0.00
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Osteopore
Its shares trade on ASX under the ticker OSX.AX. It has been listed since 23 September 2019. In the fiscal year to 31 December 2025, it reported revenue of A$3.1m and a net loss of A$3.7m. At that date it held total assets of A$2.8m and shareholders' equity of −A$1.7m.
Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic and maxillofacial surgeries. The firm is engaged in commercializing a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. The Company’s patented technology fabricates specific micro-structured scaffolds for bone regeneration through three-dimensional (3D) printing and bioresorbable material. The Company’s Osteoplug in plug and strip configuration fills craniotomy gaps effortlessly. The company also promotes bone tissue integration, from the skull to the bone flap. Its craniofacial products include Osteomesh, Osteoplug, and Osteoplug-C. The company also offers craniotomy, orbital floor reconstruction, socket preservation, cranioplasty patient-specific implants (PSI), craniosynostosis, guided bone regeneration, minimally invasive skull base surgery, endoscopic transsphenoidal skull base surgery, burr hole restoration with the shunt drainage system, mandible PSI, immediate implant loading, and more.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 23 Sept 2019
- Website
- osteopore.com ↗
Leadership
Pay as last reported
- Mr. Mark LeongExecutive Chairman of the Board, since 2021
- Dr. Lim JingChief Executive Officer, since 2023A$123,568
- Mr. Carl RundeChief Financial OfficerA$30,113
- Mr. Jack RosagroCompany Secretary
- Mr. Yujing LimDirector
- Mr. Michael KeenanNon-Executive Director
- Prof. Teoh Swee HinNon-Executive DirectorA$39,420
- Mr. Daniel OwNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Osteopore Ltd's Osteoplug fills craniotomy gaps effortlessly in neurosurgical procedures.
- Osteopore's patented 3D printing technology creates micro-structured scaffolds for bone regeneration.
- Osteopore's craniofacial products include Osteomesh, Osteoplug, and Osteoplug-C for bone healing.
Weaknesses
- Osteopore Ltd is listed in Perth, Australia, with limited international market presence.
- The company's focus on neurosurgical and orthopaedic implants may restrict broader market reach.
- Osteopore's commercialization of bespoke products requires significant R&D investment annually.
Opportunities
- Osteopore can expand its cranioplasty patient-specific implants (PSI) in the European market.
- Growing demand for minimally invasive skull base surgery offers new market opportunities.
- Osteopore's guided bone regeneration technology can be applied in dental implant procedures.
Threats
- Osteopore faces competition from established players in the Health Care sector.
- Regulatory changes in Australia could impact the approval process for new implants.
- Osteopore's reliance on bioresorbable materials may face material supply chain disruptions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.